Deep brain stimulation for obsessive–compulsive disorder: a systematic review and meta-analysis. Issue 16 (25th April 2014)

• Record Type: Journal Article
• Authors: Kisely, S.; Hall, K.; Siskind, D.; Frater, J.; Olson, S.; Crompton, D.
• Is Part Of: Psychological medicine. Volume 44:Issue 16(2014)
• Page Start: 3533
• Page End: 3542
• Publication Date: 2014-04-25
• Subjects: Deep brain stimulation, -- meta-analysis, -- neurosurgery, -- obsessive-compulsive disorder, -- YBOCS; Psychiatry -- Periodicals; Medicine and psychology -- Periodicals; Clinical psychology -- Periodicals; 616.89
• DOI: 10.1017/S0033291714000981
• Languages: English
• ISSNs: 0033-2917

Abstract

Abstract : Background: Deep brain stimulation (DBS) is increasingly being applied to psychiatric conditions such as obsessive–compulsive disorder (OCD), major depression and anorexia nervosa. Double-blind, randomized controlled trials (RCTs) of active versus sham treatment have been limited to small numbers. We therefore undertook a systematic review and meta-analysis of the effectiveness of DBS in psychiatric conditions to maximize study power. Method: We conducted a systematic literature search for double-blind, RCTs of active versus sham treatment using Pubmed/Medline and EMBASE up to April 2013. Where possible, we combined results from studies in a meta-analysis. We assessed differences in final values between the active and sham treatments for parallel-group studies and compared changes from baseline score for cross-over designs. Results: Inclusion criteria were met by five studies, all of which were of OCD. Forty-four subjects provided data for the meta-analysis. The main outcome was a reduction in obsessive symptoms as measured by the Yale–Brown Obsessive Compulsive Scale (YBOCS). Patients on active, as opposed to sham, treatment had a significantly lower mean score [mean difference (MD) −8.93, 95% confidence interval (CI) −13.35 to −5.76, p < 0.001], representing partial remission. However, one-third of patients experienced significant adverse effects ( n = 16). There were no differences between the two groups in terms of other outcomes. Conclusions: DBS may show promise for treatment-resistant OCD but there are insufficient randomized controlled data for other psychiatric conditions. DBS remains an experimental treatment in adults for severe, medically refractory conditions until further data are available.